Dihydroartemisinin Sensitizes Lung Cancer Cells to Cisplatin Treatment by Upregulating ZIP14 Expression and Inducing Ferroptosis

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Oct 12

PMID 39394878

Authors

Zhuoying Yang

Zehao Zhou

Qingyu Meng

Zhijie Chen

Liang Yun

Jianjun Jiang

Yujing He

MeiJuan Dian

Ruihao Zhang

Haotian Ge

Tianbao Yan

Biying Men

Zichao Li

Xu Wu

Junming He

Shuan Rao

Affiliations

Soon will be listed here.

Abstract

Background: Despite significant advances in lung cancer treatment, cisplatin (DDP)-based chemotherapy remains a cornerstone for managing the disease. However, the prevalence of chemoresistance presents a major challenge, limiting its effectiveness and contributing to poor outcomes. This underscores the urgent need for novel therapeutic strategies to overcome chemoresistance and improve chemotherapy efficacy in lung cancer patients. Exploring approaches to sensitize tumors to cisplatin could enhance treatment responses and overall survival rates.

Methods And Results: Our study utilized a variety of lung cancer models, including cell lines, mouse models, and patient-derived organoids, to validate the synergistic cytotoxic effects of dihydroartemisinin (DHA) and cisplatin (DDP). When combined with DDP, we demonstrate that DHA is a promising therapeutic agent that effectively triggers ferroptosis in lung cancer cells, offering a potential strategy for overcoming chemoresistance. Mechanistically, the combination of DHA and DDP synergistically enhances ZIP14 expression, modulating iron homeostasis and upregulating oxidative stress, leading to both in vitro and in vivo ferroptosis. Notably, our findings revealed that the sequential administration of DDP followed by DHA significantly increases ZIP14 expression and induces superior therapeutic outcomes compared to the simultaneous administration or DHA followed by DDP. This observation underscores the importance of the drug administration order in optimizing treatment efficacy, providing new insights into enhancing chemotherapy response in lung cancer.

Conclusion: Our findings suggest that combining dihydroartemisinin (DHA) with cisplatin (DDP) presents a promising strategy to overcome chemoresistance in lung cancer patients. Importantly, administering DHA during chemotherapy intervals could further optimize treatment outcomes, enhancing the overall efficacy of lung cancer chemotherapy.

References

Aleksakhina S, Kashyap A, Imyanitov E . Mechanisms of acquired tumor drug resistance. Biochim Biophys Acta Rev Cancer. 2019; 1872(2):188310. DOI: 10.1016/j.bbcan.2019.188310. View

Coffey R, Knutson M . The plasma membrane metal-ion transporter ZIP14 contributes to nontransferrin-bound iron uptake by human β-cells. Am J Physiol Cell Physiol. 2016; 312(2):C169-C175. PMC: 5336597. DOI: 10.1152/ajpcell.00116.2016. View

Jiang X, Stockwell B, Conrad M . Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021; 22(4):266-282. PMC: 8142022. DOI: 10.1038/s41580-020-00324-8. View

Shirai T, Tsukiji N, Sasaki T, Oishi S, Yokomori R, Takano K . Cancer-associated fibroblasts promote venous thrombosis through podoplanin/CLEC-2 interaction in podoplanin-negative lung cancer mouse model. J Thromb Haemost. 2023; 21(11):3153-3165. DOI: 10.1016/j.jtha.2023.07.005. View

Tang D, Chen X, Kang R, Kroemer G . Ferroptosis: molecular mechanisms and health implications. Cell Res. 2020; 31(2):107-125. PMC: 8026611. DOI: 10.1038/s41422-020-00441-1. View

Wong K, Yang D, Chen S, He C, Chen M . Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: A review. Asian J Pharm Sci. 2022; 17(4):475-490. PMC: 9459003. DOI: 10.1016/j.ajps.2022.04.005. View

Li S, Li F, Xu L, Liu X, Zhu X, Gao W . TLR2 agonist promotes myeloid-derived suppressor cell polarization via Runx1 in hepatocellular carcinoma. Int Immunopharmacol. 2022; 111:109168. DOI: 10.1016/j.intimp.2022.109168. View

Goldstein M, Kastan M . The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med. 2014; 66:129-43. DOI: 10.1146/annurev-med-081313-121208. View

Qu Y, Song L, Xu S, Yu M, Kadioglu O, Michelangeli F . Pomiferin targets SERCA, mTOR, and P-gp to induce autophagic cell death in apoptosis-resistant cancer cells, and reverses the MDR phenotype in cisplatin-resistant tumors in vivo. Pharmacol Res. 2023; 191:106769. DOI: 10.1016/j.phrs.2023.106769. View

10.

Li P, Jiang M, Li K, Li H, Zhou Y, Xiao X . Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity. Nat Immunol. 2021; 22(9):1107-1117. PMC: 8609402. DOI: 10.1038/s41590-021-00993-3. View

11.

Efferth T . From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol. 2017; 46:65-83. DOI: 10.1016/j.semcancer.2017.02.009. View

12.

Huang W, Wang Y, He T, Zhu J, Li J, Zhang S . Arteannuin B Enhances the Effectiveness of Cisplatin in Non-Small Cell Lung Cancer by Regulating Connexin 43 and MAPK Pathway. Am J Chin Med. 2022; 50(7):1963-1992. DOI: 10.1142/S0192415X22500847. View

13.

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

14.

Lee J, Hyun D . The Interplay between Intracellular Iron Homeostasis and Neuroinflammation in Neurodegenerative Diseases. Antioxidants (Basel). 2023; 12(4). PMC: 10135822. DOI: 10.3390/antiox12040918. View

15.

Chaft J, Shyr Y, Sepesi B, Forde P . Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(6):546-555. PMC: 8853628. DOI: 10.1200/JCO.21.01589. View

16.

Yu M, Qi B, Xiaoxiang W, Xu J, Liu X . Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF-κB pathway. Biomed Pharmacother. 2017; 90:677-685. DOI: 10.1016/j.biopha.2017.04.001. View

17.

Gao Z, Li Y, You C, Sun K, An P, Sun C . Iron Oxide Nanocarrier-Mediated Combination Therapy of Cisplatin and Artemisinin for Combating Drug Resistance through Highly Increased Toxic Reactive Oxygen Species Generation. ACS Appl Bio Mater. 2022; 1(2):270-280. DOI: 10.1021/acsabm.8b00056. View

18.

Li H, Yu K, Hu H, Zhang X, Zeng S, Li J . METTL17 coordinates ferroptosis and tumorigenesis by regulating mitochondrial translation in colorectal cancer. Redox Biol. 2024; 71:103087. PMC: 10884776. DOI: 10.1016/j.redox.2024.103087. View

19.

Li B, Shao H, Gao L, Li H, Sheng H, Zhu L . Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review. Drug Deliv. 2022; 29(1):2130-2161. PMC: 9275501. DOI: 10.1080/10717544.2022.2094498. View

20.

Lahiri A, Maji A, Potdar P, Singh N, Parikh P, Bisht B . Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023; 22(1):40. PMC: 9942077. DOI: 10.1186/s12943-023-01740-y. View